Novo Nordisk launches $9B bid to acquire U.S. obesity biotech Metsera, intensifying the race for next-generation weight-loss treatments.
Lauri Markkanen's resurgence with the Utah Jazz and the divergent trajectories of the Western Conference teams highlight the early NBA season observations.
Novo Nordisk launches $9B bid to acquire U.S. obesity biotech Metsera, intensifying the race for next-generation weight-loss treatments.
Lauri Markkanen's resurgence with the Utah Jazz and the divergent trajectories of the Western Conference teams highlight the early NBA season observations.